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Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the
upper airways frequently associated with asthma. Bacterial infection is a feature of
CRSwNP that can aggravate the disease and the response to glucocorticoid treatment.
Objective
We examined whether the bacterial product lipopolysaccharide (LPS) reduces glucocorti-
coid receptor (GR) function in control nasal mucosa (NM) fibroblasts and in nasal polyp
(NP) fibroblasts from patients with CRSwNP and asthma.
Methods
NP (n = 12) and NM fibroblasts (n = 10) were in vitro pre-incubated with LPS (24 hours) prior
to the addition of dexamethasone. Cytokine/chemokine secretion was measured by ELISA
and Cytometric Bead Array. GRα, GRβ, mitogen-activated protein-kinase phosphatase-1
(MKP-1) and glucocorticoid-induced leucine zipper (GILZ) expression was measured by
RT-PCR and immunoblotting, GRα nuclear translocation by immunocytochemistry, and
GRβ localization by immunoblotting. The role of MKP-1 and GILZ on dexamethasone-medi-
ated cytokine inhibition was analyzed by small interfering RNA silencing.
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Results
Pre-incubation of nasal fibroblasts with LPS enhanced the secretion of IL-6, CXCL8,
RANTES, and GM-CSF induced by FBS. FBS-induced CXCL8 secretion was higher in NP
than in NM fibroblasts. LPS effects on IL-6 and CXCL8 were mediated via activation of
p38α/βMAPK and IKK/NF-κB pathways. Additionally, LPS pre-incubation: 1) reduced dexa-
methasone’s capacity to inhibit FBS-induced IL-6, CXCL8 and RANTES, 2) reduced dexa-
methasone-induced GRα nuclear translocation (only in NM fibroblasts), 3) did not alter
GRα/GRβ expression, 4) decreased GILZ expression, and 5) did not affect dexametha-
sone’s capacity to induce MKP-1 and GILZ expression. MKP-1 knockdown reduced dexa-
methasone’s capacity to suppress FBS-induced CXCL8 release.
Conclusion
The bacterial product LPS negatively affects GR function in control NM and NP fibroblasts
by interfering with the capacity of the activated receptor to inhibit the production of pro-in-
flammatory mediators. This study contributes to the understanding of how bacterial infection
of the upper airways may limit the efficacy of glucocorticoid treatment.
Introduction
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the
sinus mucosa frequently associated with asthma and with aspirin-exacerbated respiratory dis-
ease [1]. Asthma and aspirin-exacerbated respiratory disease co-morbidities are a link for
CRSwNP severity [2]. In addition to persistent mucosal inflammation, microbial infection by
both Gram-positive and Gram-negative bacteria is a feature of both CRSwNP and chronic rhi-
nosinusitis without nasal polyps [3–9]. There is emerging evidence that microorganisms play
an important role in the exacerbation and perpetuation of mucosal inflammation. Intranasal
glucocorticoids, with/without administration of short courses of oral glucocorticoids, are the
first-line treatment for CRSwNP [1,10]. However, some patients with CRSwNP are not ade-
quately controlled despite guideline-based treatment with glucocorticoids. Viral and bacterial
infections, and exposure of the airways to endotoxins contribute to glucocorticoid insensitivity
[11–14].
Glucocorticoids exert their effects by binding to a cytoplasmic receptor, namely the gluco-
corticoid receptor (GR) α. The glucocorticoid-bound GRα rapidly translocates into the nucleus
and modulates, either positively or negatively, the expression of target genes. Glucocorticoid
anti-inflammatory effects are explained by inhibition of proinflammatory gene expression
through blockade of proinflammatory transcription factors, such as activating protein-1 and
nuclear factor-κB (NF-κB). Glucocorticoid anti-inflammatory effects are also explained by
transcriptional activation (transactivation) of anti-inflammatory genes [15], such as themito-
gen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) and the glucocorticoid-induced
leucine zipper (GILZ) [16,17].
The GR is a target for infectious agents. Bacterial microorganisms and their breakdown
products such as lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria,
decrease GR ligand affinity and GR number and affinity [18]. Both LPS and the Gram-negative
bacterium Haemophilus parainfluenzae attenuateMKP-1 induction by dexamethasone in
bronchoalveolar lavage (BAL) macrophages from asthmatic patients [13], and respiratory
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viruses reduceMKP-1 [11,19] and GILZ [19] induction by dexamethasone in bronchial
epithelial cells.
Human nasal fibroblasts release a variety of proinflammatory and profibrotic mediators
that can contribute to upper airways inflammation and remodeling [20,21]. Nasal fibroblasts
respond to LPS via recognition of Toll-like receptors by producing inflammatory mediators
such as the chemoattractants MCP-4, eotaxin and regulated on activation normal T cell ex-
pressed and secreted (RANTES), IL-6 and CXCL8, and growth factors such as the granulocyte/
macrophage colony-stimulating factor (GM-CSF) [22–24]. We have previously reported that
nasal polyp (NP) fibroblasts from patients with CRSwNP and asthma have a lower sensitivity
to glucocorticoids, compared to nasal mucosa (NM) fibroblasts from control patients [21,25].
We hypothesized that exposure of nasal fibroblasts to LPS reduces GR anti-inflammatory
functions, and that the effects of LPS on GR function are modulated by the presence of a pre-
existing inflammatory process, such as that of patients with CRSwNP and asthma. Therefore,
the objective of this study was to examine the effects of LPS on GR function in in vitro cultured
control NM fibroblasts and in NP fibroblasts from patients with CRSwNP and asthma. Specifi-
cally, we determined the effect of LPS on glucocorticoid-mediated inhibition of proinflamma-
tory cytokines, as well as on GR expression, nuclear translocation and transactivation of anti-
inflammatory genes. We finally evaluated the role of GR transactivation of MKP-1 and GILZ
on the inhibition of proinflammatory cytokine release mediated by glucocorticoids.
Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Lonza (Verviers, Belgium),
fetal bovine serum (FBS) from Biological Industries (Beit Haemek, Israel). Charcoal-stripped
(steroid-free) FBS (csFBS), trypsin-EDTA, penicillin, streptomycin, HEPES, RT-PCR and
immunofluorescence and Western Blot reagents, small interfering RNAs (siRNA), and all
other transfection reagents were purchased from Life Technologies (Paisley, UK). Dexametha-
sone (Fortecortin) was obtained from Merck (Darmstadt, Germany) and amphotericin B and
LPS (from Escherichia coli 0111:B4) from Sigma-Aldrich (St Louis, Missouri, USA). The
RNeasy Mini kit was purchased from Qiagen Inc. (Valencia, California, USA). All antibodies
were from Santa Cruz Biotechnology (Santa Cruz, California, USA), unless otherwise specified.
RANTES, eotaxin, GM-CSF, and CXCL8 BD Cytometric Bead Array Flex Sets were from BD
Biosciences (San Diego, California, USA), and IL-6 and CXCL8 DuoSet commercial enzyme-
linked immunosorbent assay (ELISA) kits were from R&D Systems (Abingdon, UK).
Subjects
Human NP tissue was obtained from 12 subjects with CRSwNP and asthma undergoing func-
tional endoscopic sinus surgery (S1 Table). Patients were selected on the basis of a medical his-
tory consistent with severe CRSwNP, based on established criteria described elsewhere [1,21].
The diagnosis of asthma was established on the basis of the clinical history and the demonstra-
tion of a reversible bronchial obstruction. Diagnosis of aspirin-exacerbated respiratory disease
was made on the basis of a clear-cut history of asthma attacks precipitated by non-steroidal
anti-inflammatory drugs (NSAIDs), and confirmed by aspirin nasal challenge in patients with
an isolated episode of NSAID-induced asthma exacerbation [26]. The histology of the NPs of
CRSwNP patients is predominantly eosinophilic [27,28]. Control NM was obtained from the
inferior turbinate of 10 subjects undergoing turbinectomy for turbinate hypertrophy with or
without septoplasty for nasal septum deviation. All patients gave written informed consent to
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participate in the study, which was approved by the Ethics Committee of Hospital Clínic, Bar-
celona (approval number: 2008/4291).
Fibroblast culture and treatments
Nasal fibroblasts from the tissue fragments were isolated using an explant outgrowth method
and experiments were carried out between passages 4 to 8. Cell specificity was confirmed by
positive vimentin and negative cytokeratin staining, as previously described [21]. At sub-con-
fluence, fibroblasts were pre-incubated with 10% csFBS-supplemented medium or 10% FBS-
supplemented medium (for MKP-1 protein analysis) [25] in the absence or presence of LPS
(10 μg/ml) for 24 hours. Then, dexamethasone was added and GR nuclear translocation and
transactivation was analyzed. For cytokine determination studies, after pre-incubation with/
without LPS, the cell medium was removed and changed to either 10% FBS-supplemented me-
dium or LPS (in 10% csFBS) in the absence or presence of dexamethasone for 24 hours. In
some experiments, cells were pre-incubated for 1 hour with the p38α/βMAPK inhibitor
SB203580 (10 μM), the c-Jun N-terminal kinase (JNK) inhibitor SP600125 (20 μM) or the IκB
kinase (IKK)/NF-κB inhibitor BMS-345541 (2 μM) before LPS incubation.
Small interfering RNA silencing
Thirty to 50% confluent nasal fibroblasts were transfected with 20 nM of either MKP-1 or
GILZ Silencer Select pre-designed siRNA or Silencer Select negative control siRNA using lipo-
fectamine RNAiMAX, as previously reported [29]. Twenty-four hours after transfection, cells
were pre-incubated in the absence or presence of LPS (10 μg/ml) for 24 hours. Forty-eight
hours after transfection, cells were incubated with 10% FBS-supplemented medium with/with-
out dexamethasone (10–6 M) for one (for MKP-1 protein), six (for GILZ protein) or twenty-
four (for CXCL8 release) hours.
Cell viability
Cell viability after treatment was determined using the colorimetric Cell Proliferation Kit II
(XTT, Roche Diagnostics GmbH, Mannheim, Germany), as previously reported [20].
Cytokine determination
RANTES, eotaxin, GM-CSF and CXCL8 were quantified using a specific BD Cytometric Bead
Array (CBA) Flex Set (BD Biosciences, San Diego, California, USA), as previously reported
[20]. IL-6 and CXCL8 levels were measured by using commercial enzyme-linked immunosor-
bent assay (ELISA) DuoSet kits (R&D Systems, Abingdon, UK), according to the manufactur-
er’s instructions. Cytokine production was corrected by cell number as determined by the
XTT assay.
Quantitative real-time RT-PCR
Total RNA was isolated and reverse transcribed to cDNA [29]. GRα, GRβ,MKP-1, GILZ, and
RNA polymerase II (RPII)mRNA expression was analyzed by real-time PCR using TaqMan
Fast Universal PCR Master Mix and either customized (for GRα) or predesigned (for all other
genes) TaqMan Gene Expression Assays (Life Technologies) [25]. Target gene expression was
normalized to RPII, as previously reported [25,29].
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Western Blot analysis
Whole cell protein lysates and nuclear and cytoplasmic cellular extracts from nasal fibroblasts
were obtained following previously reported protocols [25,29]. Nitrocellulose membranes were
incubated with primary antibodies against MKP-1 (C-19), GILZ (G-5), GR (E-20), GRβ (Pierce
Biotechnology, Rockford, IL, USA), β-actin (AC-15, Sigma-Aldrich), lamin-B (M-20), and α-
tubulin (B-7). Protein signals were normalized to those of α-tubulin, β-actin, or lamin-B, as
appropriate.
Immunofluorescence
Cells were incubated with an antibody against GR (E-20) and a secondary antibody conjugated
to Alexa 488, as previously reported [25]. The mean fluorescence intensity of Alexa 488 stain-
ing was assessed by analysis software within the nuclear regions of the cells. Forty to 60 cells
were analyzed for each patient and condition studied and expressed as mean fluorescence in-
tensity per mean area relative to non-treated cells at baseline (0 hours). The values of GR nucle-
ar translocation induced by dexamethasone over time were also divided by the respective
(medium or LPS) baseline values.
Statistical data analysis
Data are given as median and interquartile range. Multiple comparisons were analyzed by
using one-way analysis of variance with Tukey/Newman-Keuls post hoc analysis or with Krus-
kal-Wallis with Dunn’s post hoc analysis, as appropriate. Comparisons between two groups
were made with the t test or the Mann-Whitney U test, as appropriate. Statistical analyses were
performed with GraphPad Prism software (GraphPad Software, La Jolla, Calif; http://www.
graphpad.com). Statistical significance was set at P<.05.
Results
Effect of LPS on cytokine secretion
We first investigated the effect of LPS on the production of IL-6 by nasal fibroblasts. Maximal
IL-6 production was found in cells pre-incubated with LPS and then stimulated with 10% FBS
(Fig 1A). Pre-incubation of cells with increasing LPS concentrations resulted in higher induc-
tion of IL-6 secretion by 10% FBS (Fig 1B). LPS did not induce cytotoxicity in nasal fibroblasts
as determined by the XTT metabolic assay (data not shown). LPS pre-incubation also en-
hanced CXCL8, RANTES and GM-CSF secretion by 10% FBS, but did not increase eotaxin re-
lease (Fig 1C). In cells pre-incubated with LPS, NP fibroblasts secreted higher levels of CXCL8
in response to 10% FBS than the control NM fibroblasts.
We examined the intracellular signaling pathways involved in LPS effects. P38α/βMAPK
(SB203580) and IKK/NF-κB (BMS-34554) but not JNK (SP600125) inhibitors partially sup-
pressed the induction of IL-6 secretion by LPS in both NM and NP fibroblasts (Fig 2A).
SB203580 partially suppressed CXCL8 secretion in both NM and NP fibroblasts (Fig 2B). How-
ever, BMS-34554 and SP600125 suppressed CXCL8 only in NM fibroblasts.
Effect of LPS on dexamethasone inhibition of cytokine secretion
Dexamethasone concentration-dependently inhibited the induction of IL-6 production by 10%
FBS in both medium and LPS-pre-treated NM and NP fibroblasts (S1 Fig). LPS pre-incubation
significantly attenuated dexamethasone inhibition of FBS-induced IL-6 secretion in NM but
not in NP fibroblasts. In the absence of LPS pre-treatment, dexamethasone inhibited FBS-in-
duced CXCL8, RANTES, GM-CSF and eotaxin secretion (Fig 3). CXCL8 was less inhibited by
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dexamethasone in NP [22.69% (median) inhibition; P<.05] than in NM (66.57% inhibition) fi-
broblasts. LPS pre-incubation abrogated dexamethasone inhibition of CXCL8 secretion in both
NM and NP fibroblasts, and attenuated dexamethasone inhibition of RANTES in NM fibro-
blasts (Fig 3).
Fig 1. Effect of LPS on cytokine production. (A) ELISA quantification of IL-6 production in cell supernatants of NM and NP fibroblasts (n = 8 each) pre-
incubated with 10% csFBS-supplemented medium with/without 10 μg/ml LPS (Pre-LPS, 24 hours) and then incubated with LPS or 10% FBS-supplemented
medium (10% FBS) for 24 hours. *P<.05. (B) Effect of increasing LPS concentrations on 10% FBS-induced IL-6 production (NM and NP, n = 4–5). (C) Effect
of LPS (10 μg/ml) on 10% FBS-induced cytokine/chemokine production (NM and NP, n = 5–8). *P<.05, ** P<.01, and ***P<.001 versusmedium-
treated cells.
doi:10.1371/journal.pone.0125443.g001
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Effect of LPS on GR expression and nuclear translocation
Baseline GRα and GRβmRNA and protein levels did not differ between NM and NP fibroblasts
(data not shown). Moreover, LPS pre-incubation did not affect GRα and GRβmRNA and pro-
tein levels (S2 Fig).
At baseline, GRα was homogenously distributed within the cell in medium-treated cells (Fig
4A). GRα nuclear immunoreactivity was higher in LPS-pre-incubated cells than in medium-
treated cells (Fig 4B, 0 hours). Dexamethasone induced GRα translocation to the cell nucleus
irrespective of LPS pre-incubation in both NM and NP fibroblasts (Fig 4B). However, after di-
viding the values of GRα nuclear translocation induced by dexamethasone over time by the re-
spective (medium or LPS) baseline values, LPS reduced dexamethasone’s capacity to induce
GRα translocation in NM fibroblasts (Fig 4C). GRβ nuclear levels remained invariable after
dexamethasone and/or LPS cell stimulation (S3 Fig).
Fig 2. Effect of kinase inhibitors on LPS-induced IL-6 and CXCL8 secretion. ELISA quantification of IL-6
(A) and CXCL8 (B) production in cell supernatants of NM and NP fibroblasts (n = 4–6) incubated with 10%
csFBS-supplemented medium with/without 10 μMSB203580 (p38α/βMAPK inhibitor), 20 μMSP600125
(JNK inhibitor) or 2 μMBMS-345541 (IκB kinase/NF-κB inhibitor) for 1 hour prior to LPS (10 μg/ml) addition
for 24 hours. *P<.05 and **P<.01 versus LPS alone (100%).
doi:10.1371/journal.pone.0125443.g002
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Effect of LPS on GR transactivation of MKP-1 and GILZ
LPS pre-incubation did not significantly changeMKP-1mRNA expression in NM fibroblasts,
but increasedMKP-1mRNA levels in NP fibroblasts (Fig 5A, 0 hours). LPS did not alter GILZ
mRNA levels (Fig 5B). Dexamethasone induced the expression ofMKP-1 (Fig 5A) and GILZ
mRNAs (Fig 5B). Dexamethasone induction ofMKP-1mRNA was lower in NP than in NM fi-
broblasts [2 hours: 2.01 (median)-fold vs 5.76-fold, P<.001; 6 hours: 2.44-fold vs 3.93, P<.01].
Dexamethasone induction of GILZmRNA was also lower in NP than in NM fibroblasts [2
hours: 3.93 (median)-fold vs 10.13-fold, P<.001; 6 hours: 5.77-fold vs 12.30, P<.01; 18 hours:
5.31-fold vs 9.65, P<.01]. LPS increased dexamethasone induction ofMKP-1mRNA, but re-
duced dexamethasone induction of GILZmRNA. However, after dividing the values ofMKP-1
mRNA induction by dexamethasone by the respective control (medium or LPS) values at each
time point, LPS did not significantly reduce dexamethasone’s capacity to induceMKP-1 and
GILZmRNA in nasal fibroblasts (S4 Fig).
The effect of LPS on dexamethasone-induced transactivation of MKP-1 and GILZ at the
protein level was only analyzed in NM fibroblasts because these cells are the most sensitive to
dexamethasone. LPS pre-incubation did not significantly change MKP-1 protein (Fig 6A) but
decreased GILZ protein levels (Fig 6B). Dexamethasone induced the expression of MKP-1 and
GILZ proteins. LPS pre-incubation increased dexamethasone induction of MKP-1 but de-
creased dexamethasone induction of GILZ protein. However, after dividing the values of MKP-
1 or GILZ protein induction by dexamethasone by the respective control (medium or LPS),
LPS did not significantly reduce dexamethasone’s capacity to induce MKP-1 and GILZ pro-
teins (S5 Fig).
Role of MKP-1 and GILZ on dexamethasone inhibition of cytokine
production
We examined the involvement of MKP-1 and GILZ on the inhibition of cytokine release by
dexamethasone in six dexamethasone-sensitive NM fibroblast lines. Both MKP-1 and GILZ
proteins were effectively knocked down in MKP-1 siRNA- and GILZ siRNA-transfected NM
fibroblasts (Fig 7A). The induction of CXCL8 (Fig 7B) and IL-6 release (S6A Fig) by 10% FBS
Fig 3. Effect of LPS on dexamethasone inhibition of cytokine secretion. ELISA quantification of cytokine/chemokine production in cell supernatants of
NM and NP fibroblasts (n = 4–8) pre-incubated with 10% csFBS-supplemented medium with/without LPS (10 μg/ml, 24 hours) and then incubated with 10%
FBS-supplemented medium with/without dexamethasone (DEX: 10–6 M) for 24 hours. Cytokine production normalized to each respective control. *P<.05,
**P<.01, and ***P<.001 versusmedium (no DEX).
doi:10.1371/journal.pone.0125443.g003
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Fig 4. Effect of LPS on dexamethasone induction of GRα nuclear translocation. (A) GR immunofluorescence images of nasal fibroblasts pre-incubated
with 10% csFBS-supplemented medium with/without LPS (10 μg/ml, 24 hours) prior to dexamethasone addition (10–7 M). (B) Quantification of GRα nuclear
translocation in NM and NP fibroblasts (n = 12 each). *P<.05, **P<.01, and ***P<.001 versus 0 hours. (C) Ratio of GRα nuclear translocation induced by
dexamethasone over time to the respective (medium or LPS) baseline (0 hours) values.
doi:10.1371/journal.pone.0125443.g004
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in LPS-pre-incubated cells did not differ between negative control siRNA-transfected cells
and neither MKP-1 siRNA- nor GILZ siRNA-transfected cells. However, knockdown of MKP-
1 reduced the capacity of dexamethasone to suppress FBS-induced CXCL8 release in LPS-pre-
incubated cells (Fig 7C). This effect was not statistically significant (P =.07) for GILZ. Knock-
down of MKP-1 and GILZ did not reduce dexamethasone’s capacity to inhibit the release of
IL-6 (S6B Fig) and GM-CSF (S6C Fig) induced by FBS.
Discussion
We report the in vitro effects of LPS on GR function in primary fibroblasts from control NM
and in fibroblasts from patients with persistent chronic inflammation of the upper airways, i.e.,
patients with CRSwNP and asthma.
Previous studies have reported that nasal fibroblasts, as opposed to other airway fibroblasts,
are particularly sensitive to LPS stimulation, in terms of induction of proinflammatory
Fig 5. Effect of LPS on dexamethasone induction ofMKP-1 andGILZ gene expression.RT-PCR quantification ofMKP-1 (A) andGILZ (B) mRNAs in
NM (n = 9–10) and NP (n = 12) fibroblasts pre-incubated with 10% csFBS-supplemented medium with/without LPS (10 μg/ml, 24 hours) prior to
dexamethasone (DEX, 10–7 M) addition for the indicated times. *P<.05, **P<.01, and ***P<.001 versus untreated cells at each time point.
doi:10.1371/journal.pone.0125443.g005
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mediator release [22–24]. In our study, LPS pre-incubation enhanced the release of IL-6,
CXCL8, RANTES, and GM-CSF induced by 10% FBS in both NM and NP fibroblasts. The en-
hancement of FBS-induced CXCL8 secretion in LPS-pre-incubated cells was higher in NP than
in NM fibroblasts. Because these mediators actively participate in the recruitment and activa-
tion of inflammatory cells, their increased production in LPS-pre-treated nasal fibroblasts sug-
gests that these cells probably contribute to perpetuate the local inflammatory response during
bacterial-triggered exacerbations of the upper airways. In fact, it is known that LPS mimics the
effects of Gram-negative bacteria. Thus, LPS and Gram-negative bacteria provoke a similar in-
duction of CXCL8 in both airway smooth muscle cells [30] and BAL macrophages [13], and
the Gram-negative bacterium E. coli induces GM-CSF release—but not eotaxin release—in air-
way smooth muscle cells, as occurs in LPS-treated nasal fibroblasts.
LPS effects in structural cells are known to occur via activation of toll-like receptors and also
involving the activation of several intracellular signaling pathways, including MAPKs and NF-
κB [31]. Our experiments using intracellular pathway-specific inhibitors revealed that activa-
tion of p38 MAPK and NF-κB is involved in the induction of IL-6 production by LPS in nasal
fibroblasts. Interestingly, CXCL8 production by LPS was inhibited by p38 and JNKMAPK in-
hibitors and IKK/NF-κB inhibitor in NM but not in NP fibroblasts. This finding may be associ-
ated with the increased CXCL8 production in NP fibroblasts. These data suggest that these
kinase pathways are over-activated in NP fibroblasts, inducing CXCL8 overproduction and
possibly contributing to NP development.
The ability of dexamethasone to inhibit FBS-induced CXCL8, IL-6, and RANTES secretion
was reduced in NM fibroblasts pre-incubated with LPS. In line with this, prolonged exposure
of normal human monocytes to LPS provokes persistently increased IL-6 levels in the presence
of dexamethasone [32]. Exposure of ovalbumin-sensitised mice to LPS makes allergic airway
inflammation and hyper-responsiveness less responsive to dexamethasone [33]. In fact, infec-
tion by pathogenic microorganisms decreases glucocorticoid responsiveness in inflammatory
airway diseases [11–13,19,34,35]. For instance, the capacity of dexamethasone to inhibit IL-6
and/or CXCL8 is reduced in primary human bronchial or transformed respiratory epithelial
cells infected with either respiratory syncytial virus [19] or rhinovirus [11].
Fig 6. Effect of LPS on dexamethasone induction of MKP-1 and GILZ protein expression.Quantification of MKP-1 (A) and GILZ (B) proteins in NM
fibroblasts (n = 4–5) pre-incubated with 10% FBS (A) or 10% csFBS-supplemented medium (B) with/without LPS (10 μg/ml, 24 hours) prior to
dexamethasone (DEX, 10–7 M) addition for the indicated times. *P<.05 and **P<.01 versus untreated cells (0 hours).
doi:10.1371/journal.pone.0125443.g006
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The lower capacity of dexamethasone to inhibit FBS-induced cytokine production in LPS-
pre-incubated NM fibroblasts was not due to altered GRα/GRβ expression, but was associated
with a modestly lower capacity of dexamethasone to induce GRα nuclear translocation. Infection
of A549 cells with the respiratory syncytial virus does not alter GRα protein levels or GRα nuclear
translocation [19], but infection of the same cells with rhinovirus impairs GRα nuclear transloca-
tion [11]. A number of other factors modulate the GR response, including the interaction with
cofactors [36] and post-translational modifications of the GR, such as phosphorylation induced
by different stimuli [37,38]. Rhinovirus infection of A549 cells increases GR Ser226 phosphoryla-
tion [11], which is known to blunt GR function. However, LPS pre-incubation does not appear
to change GR Ser226 phosphorylation status in our nasal fibroblasts (unpublished data).
In immune cells, such as macrophages, MKP-1 expression is up-regulated in response to a wide
variety of proinflammatory stimuli, including ligands of the Toll-like receptors [17]. This increase
is a regulatory mechanism that inhibits MAPK activation and helps to terminate the inflammatory
cascade. However, LPS pre-incubation did not significantly increase MKP-1 expression in nasal fi-
broblasts. In contrast, LPS decreased GILZ protein expression in nasal fibroblasts. This finding
concurs with the reported GILZ down-regulation after stimulation of human alveolar macrophages
Fig 7. Role of MKP-1 and GILZ on dexamethasone inhibition of CXCL8 production. NM fibroblasts were transfected with MKP-1/GILZ/negative control
siRNAs, as indicated in Methods. Twenty-four hours later, cells were pre-incubated with/without LPS (10 μg/ml, 24 hours) prior to incubation with 10% FBS-
supplemented medium with/without dexamethasone (DEX, 10–6 M) for one (MKP-1 protein), six (GILZ protein) or twenty-four (CXCL8 release) hours. (A)
MKP-1 and GILZ protein analysis (n = 3–4). ***P<.001 versus negative control siRNA. (B) FBS-induced CXCL8 production (n = 6). **P<.01 versus no LPS.
(C) Dexamethasone inhibition of FBS-induced CXCL8 in LPS-pre-incubated cells (n = 6). *P<.05, **P<.01, and ***P<.001 versus LPS alone.
doi:10.1371/journal.pone.0125443.g007
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with LPS [39]. Noteworthy, LPS did not reduce the capacity of dexamethasone to induce MKP-1
and GILZ expression in nasal fibroblasts. This finding suggests that LPS does not affect the capacity
of glucocorticoids to transactivate anti-inflammatory genes in these cells. This contrasts with the
attenuation of dexamethasone’s ability to induce the expression ofMKP-1mRNA in A549 cells
and in primary bronchial epithelial cells infected with rhinovirus [11], and in BALmacrophages
incubated with either LPS or the bacterial pathogenH. parainfluenzae [13]. These discrepancies
may be due to differences in the stimulus/agent used and/or the cell type used.
We finally sought to determine whether transactivation of MKP-1 and GILZ by glucocorti-
coids plays an anti-inflammatory role in nasal fibroblasts. MKP-1 deficiency in macrophages
results in excessive production of numerous proinflammatory cytokines [17]. In contrast, si-
lencing of MKP-1 in nasal fibroblasts did not provoke an increase of FBS-induced CXCL8 and
IL-6 production. However, silencing of MKP-1 reduced the capacity of dexamethasone to in-
hibit FBS-induced CXCL8 production. This suggests that inhibition of CXCL8 by glucocorti-
coids occurs, at least in part, through glucocorticoid-induced MKP-1 transactivation. These
results are in line with those performed in macrophages fromMKP-1 knockout mice and in
cells with silenced expression of MKP-1 [40]. Noteworthy, the lower capacity of dexametha-
sone to decrease CXCL8 production in NP fibroblasts compared to NM fibroblasts may be due
to the lower induction of MKP-1 expression by glucocorticoids in NP fibroblasts. MKP-1 si-
lencing did not alter the inhibition of IL-6 and GM-CSF by dexamethasone. This suggests that
the inhibition of these cytokines by glucocorticoids does not occur through glucocorticoid-in-
duced MKP-1 transactivation. Our findings are consistent with the concept that not all anti-in-
flammatory effects of glucocorticoids are mediated through MKP-1 [17].
In line with studies in circulating monocytes [41], silencing of GILZ in nasal fibroblasts did
not increase FBS-induced CXCL8 and IL-6 production. GILZ silencing in nasal fibroblasts
mildly, but not significantly, attenuated dexamethasone’s inhibition of FBS-induced CXCL8
production. GILZ silencing did not affect the inhibition of IL-6 and GM-CSF by dexametha-
sone. GILZ knockdown in HEK293 cells markedly inhibited the ability of dexamethasone to
suppress IL-1β-induced CXCL8 production [42], and GILZ knockdown in circulating mono-
cytes reduced the inhibitory effect of glucocorticoids on TNF-α and RANTES secretion [41].
Overall, the involvement of MKP-1 and GILZ in glucocorticoid anti-inflammatory effects de-
pends on the cell type and the proinflammatory mediator analyzed.
In summary, pre-incubation of nasal fibroblasts with LPS enhances the secretion of the
proinflammatory mediators IL-6, CXCL8, RANTES, and GM-CSF induced by 10% FBS. FBS-
induced CXCL8 secretion is higher in NP than in NM fibroblasts. LPS pre-incubation reduces
the capacity of dexamethasone to inhibit FBS-induced IL-6, CXCL8 and RANTES production,
decreases dexamethasone-induced GRα nuclear translocation (only in NM fibroblasts), does
not alter GRα/GRβ expression, decreases GILZ expression, but does not decrease the capacity
of dexamethasone to induce GILZ and MKP-1 expression. Finally, we show that glucocorti-
coid-induced transactivation of MKP-1 is involved in CXCL8 inhibition by dexamethasone. In
conclusion, the bacterial product LPS negatively affects GR function in control NM and NP fi-
broblasts by interfering with the capacity of the activated receptor to inhibit the production of
pro-inflammatory mediators. This study contributes to the understanding of how bacterial in-
fection of the upper airways may limit the efficacy of glucocorticoid treatment.
Supporting Information
S1 Dataset. Individual data points (raw data) of Figs 1, 2, 3, 4, 5, 6 and 7 and S1, S2, S3, S4,
S5 and S6 Figs.
(XLS)
Lipopolysaccharide and Glucocorticoid Receptor Function in Fibroblasts
PLOS ONE | DOI:10.1371/journal.pone.0125443 May 5, 2015 13 / 17
S1 Fig. Effect of LPS on dexamethasone inhibition of IL-6 secretion. ELISA quantification of
IL-6 production in cell supernatants of NM and NP fibroblasts (n = 8 each) pre-incubated with
10% csFBS-supplemented medium with/without LPS (10 μg/ml, 24 hours) and then incubated
with 10% FBS-supplemented medium with/without dexamethasone (DEX) for 24 hours. IL-6
production normalized to each respective control. P<.05 and P<.001 versusmedium (no
DEX).
(TIF)
S2 Fig. Effect of LPS on GR expression.Quantification of total GRα and nuclear GRβ proteins
in NM and NP fibroblasts (n = 5–7) pre-incubated with 10% csFBS-supplemented medium
with/without LPS (10 μg/ml) for 24 hours.
(TIF)
S3 Fig. Effect of LPS on GRβ nuclear translocation. Quantification of GRβ nuclear transloca-
tion in response to dexamethasone (10–7 M, 1 hour) in NM and NP (n = 5 each) fibroblasts
pre-incubated with 10% csFBS-supplemented medium with/without LPS for 24 hours. Repre-
sentative GRβWestern blot images are shown. Lamin B was used as loading control and α-tu-
bulin was used to assure purity of the nuclear extracts.
(TIF)
S4 Fig. Effect of LPS on dexamethasone induction ofMKP-1 and GILZ gene expression.
RT-PCR quantification ofMKP-1 (A) and GILZ (B) mRNAs in NM (n = 9–10) and NP
(n = 12) fibroblasts pre-incubated with 10% csFBS-supplemented medium with/without LPS
(10 μg/ml, 24 hours) prior to dexamethasone (DEX, 10–7 M) addition for the indicated times.
Data show the ratio ofMKP-1 or GILZmRNA induction by dexamethasone to the respective
control (medium or LPS) at each time point.
(TIF)
S5 Fig. Effect of LPS on dexamethasone induction of MKP-1 and GILZ protein expression.
Quantification of MKP-1 (A) and GILZ (B) proteins in NM fibroblasts (n = 4–5) pre-incubated
with 10% FBS (A) or 10% csFBS-supplemented medium (B) with/without LPS (10 μg/ml, 24
hours) prior to dexamethasone (DEX, 10–7 M) addition for one (A) or 18 hours (B). Data show
the ratio of MKP-1 or GILZ protein induction by dexamethasone to the respective control (me-
dium or LPS).
(TIF)
S6 Fig. Role of MKP-1 and GILZ on dexamethasone inhibition of IL-6 and GM-CSF pro-
duction. NM fibroblasts (n = 6) were transfected with MKP-1/GILZ/negative control siRNAs,
as indicated in Methods. Twenty-four hours later, cells were pre-incubated with/without LPS
(10 μg/ml, 24 hours) prior to incubation with 10% FBS-supplemented medium with/without
dexamethasone (DEX, 10–6 M) for 24 hours. (A) FBS-induced IL-6 production. P<.01 versus
no LPS. Dexamethasone inhibition of FBS-induced IL-6 (B) and GM-CSF (C) release in LPS-
pre-incubated cells. P<.001 versus LPS alone.
(TIF)
S7 Fig. Original uncropped Western blot images of Fig 6A and 6B.
(TIF)
S8 Fig. Original uncropped Western blot images of Fig 7A.
(TIF)
S9 Fig. Original uncropped Western blot images of S3 Fig.
(TIF)
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S1 Table. Epidemiological characteristics of the study population.
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